Enlivex Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Enlivex Therapeutics's earnings are forecast to decline at 22.7% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.5% pro Jahr.

Wichtige Informationen

-22.7%

Wachstumsrate der Gewinne

4.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.4%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:1BT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-27	-27	-27	1
12/31/2025	N/A	-14	-14	-14	2
12/31/2024	N/A	-13	-12	-14	2
6/30/2024	N/A	-22	-17	-17	N/A
3/31/2024	N/A	-26	-22	-22	N/A
12/31/2023	N/A	-29	-24	-24	N/A
9/30/2023	N/A	-27	-26	-23	N/A
6/30/2023	N/A	-27	-28	-24	N/A
3/31/2023	N/A	-30	-34	-26	N/A
12/31/2022	N/A	-31	-32	-24	N/A
9/30/2022	N/A	-29	-32	-26	N/A
6/30/2022	N/A	-26	-29	-23	N/A
3/31/2022	N/A	-19	-21	-18	N/A
12/31/2021	N/A	-14	-19	-18	N/A
9/30/2021	N/A	-16	-18	-17	N/A
6/30/2021	N/A	-14	-16	-15	N/A
3/31/2021	N/A	-14	-15	-14	N/A
12/31/2020	N/A	-12	-12	-11	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-9	-7	-7	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-10	-7	-7	N/A
9/30/2019	N/A	-9	-7	-6	N/A
6/30/2019	N/A	-7	-6	-5	N/A
3/31/2019	N/A	-7	-4	-3	N/A
12/31/2018	N/A	-5	-4	-3	N/A
9/30/2018	N/A	-4	-3	-3	N/A
12/31/2017	N/A	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1BT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 1BT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 1BT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 1BT schneller wachsen werden als der Markt von German.

Hohe Wachstumseinnahmen: 1BT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1BT in 3 Jahren voraussichtlich hoch sein wird

Enlivex Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

New major risk - Revenue and earnings growth

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

New major risk - Financial position

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Insufficient new directors

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

Enlivex Therapeutics Ltd.: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Enlivex Awards Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Enlivex Therapeutics Ltd Receives Notice of Allowance for Japanese Patent Application

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Announces Issuance of U.S. Patent No. 10,927,343 Covering AllocetraTM, the Immunotherapy Product Candidate

Enlivex Therapeutics Ltd. Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update

New 90-day high: €10.90

Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on Medrxiv

Enlivex Therapeutics Ltd Reports Positive Interim Results of an Investigator-Initiated Phase Ii Clinical Trial Evaluating Allocetratm in Severe and Critical Covid-19 Patients

Enlivex Therapeutics Ltd. Reports Positive Two-Year Clinical Outcome for Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

Enlivex Appoints Dr. Brian Schwartz to the Board of Directors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Reports That the Israeli Ministry of Health Authorized the Initiation of a Proposed Investigator-Initiated Phase II Clinical Trial Evaluating AllocetraTM in Severe and Critical COVID-19 Patients

Enlivex Therapeutics Ltd Reports Positive Top-Line Results of an Investigator-Initiated Clinical Trial of Allocetratm in COVID-19 Patients in Severe/Critical Condition

New 90-day high: €7.40

Enlivex Therapeutics Ltd. Receives New Patent Application Covering ALLOCETRA™

New 90-day low - €3.88

New 90-day low - €4.32

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken